Cargando…
Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma
Background: Recent studies have demonstrated benefits from adjuvant tyrosine-kinase inhibitors (TKIs) compared with chemotherapy in non-small cell lung cancer. We launched a multi-center retrospective study to evaluate the efficacy and toxicity of adjuvant TKIs with or without chemotherapy in epider...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167779/ https://www.ncbi.nlm.nih.gov/pubmed/33916930 http://dx.doi.org/10.3390/curroncol28020135 |
_version_ | 1783701761252392960 |
---|---|
author | Li, Qiwen Ma, Li Qiu, Bo Wen, Yuzhi Liang, Wenhua Hu, Wanming Chen, Naibin Zhang, Tian Xu, Shuangbing Chen, Lingjuan Guo, Minzhang Zhao, Yi Liu, Songran Guo, Jinyu Wang, Junye Wang, Siyu Wang, Xin Pang, Qingsong Long, Hao Liu, Hui |
author_facet | Li, Qiwen Ma, Li Qiu, Bo Wen, Yuzhi Liang, Wenhua Hu, Wanming Chen, Naibin Zhang, Tian Xu, Shuangbing Chen, Lingjuan Guo, Minzhang Zhao, Yi Liu, Songran Guo, Jinyu Wang, Junye Wang, Siyu Wang, Xin Pang, Qingsong Long, Hao Liu, Hui |
author_sort | Li, Qiwen |
collection | PubMed |
description | Background: Recent studies have demonstrated benefits from adjuvant tyrosine-kinase inhibitors (TKIs) compared with chemotherapy in non-small cell lung cancer. We launched a multi-center retrospective study to evaluate the efficacy and toxicity of adjuvant TKIs with or without chemotherapy in epidermal growth factor receptor (EGFR)-mutant stage III-pN2 lung adenocarcinoma. Methods: Two hundred and seventy-four consecutive cases with stage III-pN2 lung adenocarcinoma and complete resection have been investigated. Clinic-pathologic characteristics, adjuvant treatments, long-term survivals, and toxicities were documented. Risk factors of distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were evaluated. Results: There were 52 (19.0%) patients treated with adjuvant TKIs alone, 199 (72.6%) with adjuvant chemotherapy alone, and 23 (8.4%) with both. After a median follow-up time of 29 months, the two-year DMFS, DFS, and OS was 61.2%, 54.1%, and 91.2%, respectively. According to univariable analyses, the risk factors were lymphovascular invasion (p < 0.001), extranodal extension (p = 0.005), and adjuvant systemic therapy (p = 0.006) for DMFS, EGFR mutation type (p = 0.025), lymphovascular invasion (p = 0.013), extranodal extension (p = 0.004), and adjuvant systemic therapy (p < 0.001) for DFS, and EGFR mutation type (p < 0.001) for OS. Multivariable analyses indicated that the independent prognostic factors were adjuvant systemic therapy (TKIs vs. TKIs+chemotherapy, Harzard ratio (HR) = 0.40; p = 0.036; TKIs vs. chemotherapy, HR = 0.38; p = 0.004), lymphovascular invasion (yes vs. no, HR = 2.22; p = 0.001) for DMFS, and adjuvant systemic therapy (TKIs vs. TKIs+chemotherapy, HR = 0.42; p = 0.034; TKIs vs. chemotherapy, HR = 0.33; p < 0.001) for DFS. No significant difference was found in the incidence of Grade 3–4 toxicities between groups (p = 0.445). Conclusions: Adjuvant TKIs might be a beneficial choice compared with adjuvant chemotherapy or combination systemic treatments. |
format | Online Article Text |
id | pubmed-8167779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81677792021-06-02 Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma Li, Qiwen Ma, Li Qiu, Bo Wen, Yuzhi Liang, Wenhua Hu, Wanming Chen, Naibin Zhang, Tian Xu, Shuangbing Chen, Lingjuan Guo, Minzhang Zhao, Yi Liu, Songran Guo, Jinyu Wang, Junye Wang, Siyu Wang, Xin Pang, Qingsong Long, Hao Liu, Hui Curr Oncol Article Background: Recent studies have demonstrated benefits from adjuvant tyrosine-kinase inhibitors (TKIs) compared with chemotherapy in non-small cell lung cancer. We launched a multi-center retrospective study to evaluate the efficacy and toxicity of adjuvant TKIs with or without chemotherapy in epidermal growth factor receptor (EGFR)-mutant stage III-pN2 lung adenocarcinoma. Methods: Two hundred and seventy-four consecutive cases with stage III-pN2 lung adenocarcinoma and complete resection have been investigated. Clinic-pathologic characteristics, adjuvant treatments, long-term survivals, and toxicities were documented. Risk factors of distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were evaluated. Results: There were 52 (19.0%) patients treated with adjuvant TKIs alone, 199 (72.6%) with adjuvant chemotherapy alone, and 23 (8.4%) with both. After a median follow-up time of 29 months, the two-year DMFS, DFS, and OS was 61.2%, 54.1%, and 91.2%, respectively. According to univariable analyses, the risk factors were lymphovascular invasion (p < 0.001), extranodal extension (p = 0.005), and adjuvant systemic therapy (p = 0.006) for DMFS, EGFR mutation type (p = 0.025), lymphovascular invasion (p = 0.013), extranodal extension (p = 0.004), and adjuvant systemic therapy (p < 0.001) for DFS, and EGFR mutation type (p < 0.001) for OS. Multivariable analyses indicated that the independent prognostic factors were adjuvant systemic therapy (TKIs vs. TKIs+chemotherapy, Harzard ratio (HR) = 0.40; p = 0.036; TKIs vs. chemotherapy, HR = 0.38; p = 0.004), lymphovascular invasion (yes vs. no, HR = 2.22; p = 0.001) for DMFS, and adjuvant systemic therapy (TKIs vs. TKIs+chemotherapy, HR = 0.42; p = 0.034; TKIs vs. chemotherapy, HR = 0.33; p < 0.001) for DFS. No significant difference was found in the incidence of Grade 3–4 toxicities between groups (p = 0.445). Conclusions: Adjuvant TKIs might be a beneficial choice compared with adjuvant chemotherapy or combination systemic treatments. MDPI 2021-04-07 /pmc/articles/PMC8167779/ /pubmed/33916930 http://dx.doi.org/10.3390/curroncol28020135 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Li, Qiwen Ma, Li Qiu, Bo Wen, Yuzhi Liang, Wenhua Hu, Wanming Chen, Naibin Zhang, Tian Xu, Shuangbing Chen, Lingjuan Guo, Minzhang Zhao, Yi Liu, Songran Guo, Jinyu Wang, Junye Wang, Siyu Wang, Xin Pang, Qingsong Long, Hao Liu, Hui Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma |
title | Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma |
title_full | Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma |
title_fullStr | Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma |
title_full_unstemmed | Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma |
title_short | Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma |
title_sort | benefit from adjuvant tkis versus tkis plus chemotherapy in egfr-mutant stage iii-pn2 lung adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167779/ https://www.ncbi.nlm.nih.gov/pubmed/33916930 http://dx.doi.org/10.3390/curroncol28020135 |
work_keys_str_mv | AT liqiwen benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT mali benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT qiubo benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT wenyuzhi benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT liangwenhua benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT huwanming benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT chennaibin benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT zhangtian benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT xushuangbing benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT chenlingjuan benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT guominzhang benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT zhaoyi benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT liusongran benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT guojinyu benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT wangjunye benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT wangsiyu benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT wangxin benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT pangqingsong benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT longhao benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma AT liuhui benefitfromadjuvanttkisversustkispluschemotherapyinegfrmutantstageiiipn2lungadenocarcinoma |